SGLT2 inhibitors work by blocking glucose reabsorption at SGLT2 channels in the proximal convoluted tubule of the kidney and therefore lower glucose independently of insulin, avoiding hypoglycemia and weight gain, which are associated with insulin or its secretagogues. The gene discussed is SLC5A2; the disease is Hypoglycemia.